Your browser is no longer supported. Please, upgrade your browser.
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own7.20% Shs Outstand128.12M Perf Week-1.86%
Market Cap1.62B Forward P/E- EPS next Y-0.55 Insider Trans-0.10% Shs Float116.08M Perf Month15.33%
Income- PEG- EPS next Q-0.14 Inst Own50.90% Short Float7.35% Perf Quarter-11.30%
Sales50.12M P/S32.31 EPS this Y-53.00% Inst Trans- Short Ratio2.36 Perf Half Y-14.82%
Book/sh3.22 P/B3.93 EPS next Y45.50% ROA- Target Price11.50 Perf Year-18.50%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range9.72 - 20.50 Perf YTD-8.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.90% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low26.75% ATR0.75
Employees294 Current Ratio- Sales Q/Q172417.20% Oper. Margin- RSI (14)45.12 Volatility3.69% 5.34%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.66 Prev Close12.64
ShortableYes LT Debt/Eq- EarningsMay 06 AMC Payout- Avg Volume3.62M Price12.32
Recom1.70 SMA20-6.06% SMA50-2.07% SMA200-12.17% Volume2,209,722 Change-2.53%
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Mar-16-18Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Jun-14-21 06:05AM  
Jun-07-21 07:05PM  
May-27-21 06:05AM  
May-21-21 07:58AM  
May-20-21 04:05PM  
May-19-21 10:00AM  
May-14-21 06:05AM  
May-13-21 09:22AM  
May-10-21 05:47PM  
May-06-21 07:45PM  
Apr-28-21 06:30AM  
Apr-26-21 06:59AM  
Apr-15-21 06:05AM  
Apr-08-21 07:38AM  
Mar-31-21 01:36AM  
Mar-15-21 08:52AM  
Mar-11-21 07:45AM  
Mar-02-21 06:05AM  
Feb-25-21 12:00AM  
Feb-24-21 04:02PM  
Feb-23-21 10:29AM  
Feb-18-21 06:05AM  
Feb-17-21 06:05AM  
Feb-14-21 02:08AM  
Feb-11-21 05:30PM  
Feb-01-21 07:45AM  
Jan-27-21 11:05AM  
Jan-26-21 08:07AM  
Jan-25-21 04:22PM  
Jan-22-21 08:24PM  
Jan-11-21 09:56AM  
Jan-08-21 06:05AM  
Jan-02-21 10:45AM  
Dec-30-20 11:08AM  
Dec-28-20 08:32AM  
Dec-21-20 03:40PM  
Dec-17-20 11:02AM  
Dec-16-20 07:15AM  
Dec-15-20 05:59PM  
Dec-02-20 06:05AM  
Nov-29-20 06:44AM  
Nov-20-20 05:00PM  
Nov-12-20 04:05PM  
Nov-11-20 08:45AM  
Nov-10-20 05:15PM  
Nov-09-20 04:05PM  
Nov-05-20 12:30PM  
Nov-04-20 02:25PM  
Nov-03-20 07:38AM  
Nov-02-20 04:05PM  
Oct-28-20 07:41AM  
Oct-27-20 04:05PM  
Oct-22-20 04:15PM  
Oct-16-20 06:28AM  
Oct-14-20 06:05AM  
Oct-05-20 01:30PM  
Oct-02-20 05:00PM  
Sep-29-20 06:44PM  
Sep-28-20 06:05AM  
Sep-16-20 03:26PM  
Sep-10-20 06:05AM  
Sep-04-20 06:04PM  
Aug-11-20 05:29PM  
Aug-04-20 12:30PM  
Jul-30-20 06:05AM  
Jul-28-20 12:33PM  
Jul-27-20 10:15AM  
Jul-23-20 06:59PM  
Jul-22-20 11:05PM  
Jul-21-20 05:27PM  
Jul-18-20 10:02AM  
Jul-15-20 01:15PM  
Jul-12-20 08:15PM  
Jun-22-20 06:05AM  
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MacKay-Dunn R. HectorDirectorMay 12Buy11.273,00033,8046,000May 13 04:17 PM
Martin Michael RobertChief Business OfficerMay 11Option Exercise3.0220,00060,400221,861May 12 04:30 PM
Huizinga Robert BindertEx Vice President of ResearchMay 11Option Exercise3.0240,000120,800143,592May 11 05:22 PM
Miller Joseph MChief Financial OfficerMay 11Buy9.741,0009,7401,000May 11 04:53 PM
MacKay-Dunn R. HectorDirectorMay 11Buy11.151,50016,7253,000May 13 04:17 PM
Donley Matthew MaxwellEx VP, Intern'l OperationsMay 11Buy10.079,90099,7399,900May 12 04:34 PM
Greenleaf PeterChief Executive OfficerMay 11Buy10.715,12554,89113,453May 12 04:32 PM
Leversage JillDirectorMay 11Buy10.962,50027,3893,700May 12 04:28 PM
Solomons NeilChief Medical OfficerMar 12Option Exercise3.0240,000120,800227,299Mar 15 04:36 PM
Solomons NeilChief Medical OfficerMar 12Sale13.4940,000539,600187,299Mar 15 04:36 PM
MILNE GEORGE M JRDirectorMar 05Buy13.005,00065,00045,000Mar 09 04:25 PM
Hayden Michael RDirectorJan 29Option Exercise5.7995,000550,10095,000Feb 02 03:18 PM
Leversage JillDirectorJan 29Buy16.034006,412400Feb 02 03:22 PM
Leversage JillDirectorJan 29Buy16.031,20019,2361,200Feb 02 03:22 PM
Robertson Stephen P.EVP, General CounselJan 28Buy16.1490014,5262,720Jan 29 12:24 PM